Skip to Main Content

Paper Details

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.
Neurooncol Adv
5
2021
GBM, Macitentan, TMZ, endothelin receptor, glioblastoma, macitentan, patients, recurrent GBM, recurrent glioblastoma, temozolomide, tumors
Author NameAffiliation
John F de GrootUniversity of Texas MD Anderson Cancer Center
Vinay K PuduvalliThe Ohio State University Comprehensive Cancer Center
Wai-Kwan Alfred YungUniversity of Texas MD Anderson Cancer Center
Wai-Kwan Alfred YungUniversity of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2